Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer.

This present study takes the previous studies further by showing that dacomitinib produced a highly significant growth inhibition in the xenograft models of these cell lines ( Table 2 ).

also in 132,142 other papers